6657 Stock Overview
Operates in the biomedicine industry in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Energenesis Biomedical CO.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$57.00 |
| 52 Week High | NT$68.50 |
| 52 Week Low | NT$45.90 |
| Beta | 0.57 |
| 11 Month Change | 10.47% |
| 3 Month Change | 9.41% |
| 1 Year Change | -14.54% |
| 33 Year Change | 23.91% |
| 5 Year Change | -32.76% |
| Change since IPO | 83.87% |
Recent News & Updates
Shareholder Returns
| 6657 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 16.2% | -1.0% | 0.8% |
| 1Y | -14.5% | 0.7% | 30.3% |
Return vs Industry: 6657 underperformed the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 6657 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6657 volatility | |
|---|---|
| 6657 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6657 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6657's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 35 | Han-min Chen | www.energenesis-biomedical.com |
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.
Energenesis Biomedical CO.,LTD. Fundamentals Summary
| 6657 fundamental statistics | |
|---|---|
| Market cap | NT$4.15b |
| Earnings (TTM) | -NT$243.52m |
| Revenue (TTM) | NT$7.39m |
588.1x
P/S Ratio-17.8x
P/E RatioIs 6657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6657 income statement (TTM) | |
|---|---|
| Revenue | NT$7.39m |
| Cost of Revenue | NT$2.00m |
| Gross Profit | NT$5.39m |
| Other Expenses | NT$248.91m |
| Earnings | -NT$243.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.19 |
| Gross Margin | 72.92% |
| Net Profit Margin | -3,296.18% |
| Debt/Equity Ratio | 0% |
How did 6657 perform over the long term?
See historical performance and comparison